{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:36:47Z","timestamp":1779935807921,"version":"3.53.1"},"reference-count":77,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Limited information exists regarding the impact of pharmacotherapy in pregnancy due to ethical concerns of unintended fetal harm. Yet, maternal prescriptive drug use for chronic conditions such as hypertension is common.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate potential causal relationships between perturbing maternal genetic variants influencing antihypertensive drug targets and perinatal outcomes among offspring using mendelian randomization (MR).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This 2-sample MR study used individual-level single-nucleotide variation (SNV) outcome data from mother-father-offspring trios with complete genetic and phenotypic information from the Norwegian Mother, Father and Child Cohort Study (MoBa) and summary-level SNV exposure data from UK Biobank participants sourced from the Integrative Epidemiology Unit OpenGWAS project. Pregnant individuals were recruited across Norway during their routine ultrasonography examination at 18 weeks\u2019 gestation between June 1999 and December 2008, and mothers, fathers, and offspring were followed up after birth. Novel genetic instruments for maternal antihypertensive drug targets that act via systolic blood pressure (SBP) were derived from individual-level data analyzed in January 2018. Two-sample multivariable MR analysis of these maternal drug targets and offspring outcomes were performed between January 2023 and April 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Maternal genetic variants associated with drug targets for treatments of hypertension, as specified in the National Health Service dictionary of medicines and devices.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Offspring outcomes were Apgar score at 1 minute and 5 minutes, offspring developmental score at 6 months, birth length, birth weight z <\/jats:italic>score, gestational age, head circumference, and congenital malformation. Maternal hypertensive disorders of pregnancy were a positive control.<\/jats:p><\/jats:sec>Results<\/jats:title>The MoBa sample contained 29\u202f849 family trios, with a mean (SD) maternal age of 30.2 (18.6) years and a mean (SD) paternal age of 32.8 (13.1) years; 51.1% of offspring were male. Seven independent SNVs were identified as influencing maternal SBP via the antihypertensive drug target instruments. For higher levels of maternal SBP acting through the CACNB2<\/jats:italic> calcium channel blocker target, the estimated change in gestational age was 3.99 days (95% CI, 0.02-7.96 days) per 10-mm Hg decrease in SBP. There was no evidence of differential risk for measured perinatal outcomes from maternal SBP acting through drug targets for multiple hypertensive subclasses, such as between the ADRB1<\/jats:italic> \u03b2-adrenoceptor\u2013blocking target and risk of congenital malformation (estimated odds ratio, 0.28 [95% CI, 0.02-4.71] per 10-mm Hg decrease in SBP). Maternal and paternal SBP acting through the EDNRA<\/jats:italic> vasodilator antihypertensive target did not have a potential causal effect on birth weight z<\/jats:italic> score, with respective \u03b2 estimates of 0.71 (95% CI, \u22120.09 to 1.51) and 0.72 (95% CI, \u22120.08 to 1.53) per 10-mm Hg decrease in SBP.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings provided little evidence to indicate that perturbation of maternal genetic variants for SBP that influence antihypertensive drug targets had potential causal relationships with measures of perinatal development and health within this study. These findings may be triangulated with existing literature to guide physicians and mothers in decisions about antihypertensive use during pregnancy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.26234","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:00:50Z","timestamp":1724770850000},"page":"e2426234","source":"Crossref","is-referenced-by-count":2,"title":["Genetic Insights Into Perinatal Outcomes of Maternal Antihypertensive Therapy During Pregnancy"],"prefix":"10.1001","volume":"7","author":[{"given":"Ciarrah-Jane S.","family":"Barry","sequence":"first","affiliation":[{"name":"Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom"},{"name":"Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venexia M.","family":"Walker","sequence":"additional","affiliation":[{"name":"Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom"},{"name":"Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"},{"name":"Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Burden","sequence":"additional","affiliation":[{"name":"Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Havdahl","sequence":"additional","affiliation":[{"name":"Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom"},{"name":"Nic Waals Institute, Lovisenberg Diaconal Hospital, Oslo, Norway"},{"name":"Center for Genetic Epidemiology and Mental Health, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"PROMENTA, Department of Psychology, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.","family":"Davies","sequence":"additional","affiliation":[{"name":"Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom"},{"name":"K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway"},{"name":"Division of Psychiatry, University College London, London, United Kingdom"},{"name":"Department of Statistical Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"issue":"3","key":"zoi240817r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3808","article-title":"Prevalence of hypertension among pregnant women when using the 2017 American College of Cardiology\/American Heart Association blood pressure guidelines and association with maternal and fetal outcomes.","volume":"4","author":"Bello","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi240817r3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.12703\/b","article-title":"Recent advances in the diagnosis and management of pre-eclampsia.","volume":"9","author":"Hurrell","year":"2020","journal-title":"Fac Rev"},{"issue":"7","key":"zoi240817r4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029908","article-title":"Prevalence and risk of pre-eclampsia and gestational hypertension in twin pregnancies: a population-based register study.","volume":"9","author":"Laine","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"zoi240817r5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1186\/s12887-022-03542-5","article-title":"A review of infant growth and psychomotor developmental outcomes after intrauterine exposure to preeclampsia.","volume":"22","author":"Vakil","year":"2022","journal-title":"BMC Pediatr"},{"issue":"2","key":"zoi240817r6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5830\/CVJA-2016-021","article-title":"Physiological changes in pregnancy.","volume":"27","author":"Soma-Pillay","year":"2016","journal-title":"Cardiovasc J Afr"},{"issue":"8","key":"zoi240817r7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1053\/j.semperi.2014.08.011","article-title":"Basic obstetric pharmacology.","volume":"38","author":"Zhao","year":"2014","journal-title":"Semin Perinatol"},{"issue":"11","key":"zoi240817r8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002160","article-title":"Pregnancy-associated changes in pharmacokinetics: a systematic review.","volume":"13","author":"Pariente","year":"2016","journal-title":"PLoS Med"},{"issue":"3","key":"zoi240817r9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics.","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"zoi240817r10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/bdrc.v105.2","article-title":"Thalidomide-induced teratogenesis: history and mechanisms.","volume":"105","author":"Vargesson","year":"2015","journal-title":"Birth Defects Res C Embryo Today"},{"issue":"6","key":"zoi240817r11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3109\/01443615.2011.579197","article-title":"Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.","volume":"31","author":"Walfisch","year":"2011","journal-title":"J Obstet Gynaecol"},{"issue":"23","key":"zoi240817r12","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa055202","article-title":"Major congenital malformations after first-trimester exposure to ACE inhibitors.","volume":"354","author":"Cooper","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi240817r13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1253\/circj.CJ-15-0617","article-title":"Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease.","volume":"80","author":"Tanaka","year":"2016","journal-title":"Circ J"},{"issue":"5","key":"zoi240817r14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/AOG.0b013e3182a9ca67","article-title":"Exclusion of pregnant women from industry-sponsored clinical trials.","volume":"122","author":"Shields","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"3","key":"zoi240817r16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0731","article-title":"Late pregnancy \u00df blocker exposure and risks of neonatal hypoglycemia and bradycardia.","volume":"138","author":"Bateman","year":"2016","journal-title":"Pediatrics"},{"issue":"1","key":"zoi240817r17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13690-020-00423-0","article-title":"Adherence to drug therapy for hypertensive disorders of pregnancy: a cross-sectional survey.","volume":"78","author":"Chen","year":"2020","journal-title":"Arch Public Health"},{"key":"zoi240817r18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.preghy.2021.06.002","article-title":"Adherence to anti-hypertensive medication in pregnancy.","volume":"25","author":"Helou","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"zoi240817r19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.12688\/wellcomeopenres","article-title":"Guidelines for performing mendelian randomization investigations: update for summer 2023.","volume":"4","author":"Burgess","year":"2023","journal-title":"Wellcome Open Res"},{"key":"zoi240817r20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12688\/wellcomeopenres","article-title":"Mendelian randomization for studying the effects of perturbing drug targets.","volume":"6","author":"Gill","year":"2021","journal-title":"Wellcome Open Res"},{"issue":"1","key":"zoi240817r21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization.","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Primers"},{"issue":"2","key":"zoi240817r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228951","article-title":"Segregation distortion: utilizing simulated genotyping data to evaluate statistical methods.","volume":"15","author":"Coulton","year":"2020","journal-title":"PLoS One"},{"key":"zoi240817r23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.12688\/wellcomeopenres","article-title":"Using mendelian randomization to determine causal effects of maternal pregnancy (intrauterine) exposures on offspring outcomes: sources of bias and methods for assessing them.","volume":"2","author":"Lawlor","year":"2017","journal-title":"Wellcome Open Res"},{"issue":"1","key":"zoi240817r24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/ije\/dyh132","article-title":"Mendelian randomization: prospects, potentials, and limitations.","volume":"33","author":"Davey Smith","year":"2004","journal-title":"Int J Epidemiol"},{"issue":"4","key":"zoi240817r25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s40471-017-0128-6","article-title":"Recent developments in Mendelian randomization studies.","volume":"4","author":"Zheng","year":"2017","journal-title":"Curr Epidemiol Rep"},{"issue":"6","key":"zoi240817r26","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/ije\/dyx207","article-title":"Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities.","volume":"46","author":"Walker","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"4","key":"zoi240817r27","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/ije\/dyz155","article-title":"Repurposing antihypertensive drugs for the prevention of Alzheimer\u2019s disease: a mendelian randomization study.","volume":"49","author":"Walker","year":"2020","journal-title":"Int J Epidemiol"},{"key":"zoi240817r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104038","article-title":"Using Mendelian randomisation to identify opportunities for type 2 diabetes prevention by repurposing medications used for lipid management.","volume":"80","author":"Khankari","year":"2022","journal-title":"eBioMedicine"},{"issue":"1","key":"zoi240817r29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005623","article-title":"Mendelian randomization in cardiovascular research: establishing causality when there are unmeasured confounders.","volume":"14","author":"Bell","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"zoi240817r30","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.1038\/s41467-021-26280-1","article-title":"Finding genetically-supported drug targets for Parkinson\u2019s disease using mendelian randomization of the druggable genome.","volume":"12","author":"Storm","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"zoi240817r31","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12916-022-02483-1","article-title":"Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: a mendelian randomization study.","volume":"20","author":"Ardissino","year":"2022","journal-title":"BMC Med"},{"issue":"3","key":"zoi240817r33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"issue":"7726","key":"zoi240817r34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data.","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"issue":"2","key":"zoi240817r35","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/ije\/dyw029","article-title":"Cohort profile update: the Norwegian Mother and Child Cohort Study (MoBa).","volume":"45","author":"Magnus","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"5","key":"zoi240817r36","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/ije\/dyl170","article-title":"Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa).","volume":"35","author":"Magnus","year":"2006","journal-title":"Int J Epidemiol"},{"issue":"6","key":"zoi240817r38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1034\/j.1600-0412.2000.079006435.x","article-title":"The Medical Birth Registry of Norway: epidemiological research and surveillance throughout 30 years.","volume":"79","author":"Irgens","year":"2000","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1\u20132","key":"zoi240817r39","doi-asserted-by":"publisher","DOI":"10.5324\/nje.v24i1-2.1755","article-title":"The biobank of the Norwegian Mother and Child Cohort Study\u2014present status.","volume":"24","author":"Paltiel","year":"2014","journal-title":"Nor Epidemiol"},{"issue":"D1","key":"zoi240817r43","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018.","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"zoi240817r44","doi-asserted-by":"publisher","first-page":"D766","DOI":"10.1093\/nar\/gky955","article-title":"GENCODE reference annotation for the human and mouse genomes.","volume":"47","author":"Frankish","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"zoi240817r45","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/bjo.v131.3","article-title":"Major postpartum haemorrhage after frozen embryo transfer: a population-based study.","volume":"131","author":"Al-Khatib","year":"2024","journal-title":"BJOG"},{"key":"zoi240817r46","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome.","volume":"7","author":"Hemani","year":"2018","journal-title":"Elife"},{"issue":"7404","key":"zoi240817r48","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"issue":"7280","key":"zoi240817r49","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/bmj.322.7280.226","article-title":"Sifting the evidence\u2014what\u2019s wrong with significance tests?","volume":"322","author":"Sterne","year":"2001","journal-title":"BMJ"},{"issue":"2","key":"zoi240817r50","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/EDE.0b013e318245912c","article-title":"Negative control exposures in epidemiologic studies.","volume":"23","author":"Davey Smith","year":"2012","journal-title":"Epidemiology"},{"issue":"3","key":"zoi240817r51","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2307\/2171753","article-title":"Instrumental variables regression with weak instruments.","volume":"65","author":"Staiger","year":"1997","journal-title":"Econometrica"},{"issue":"R2","key":"zoi240817r52","doi-asserted-by":"publisher","first-page":"R195","DOI":"10.1093\/hmg\/ddy163","article-title":"Evaluating the potential role of pleiotropy in Mendelian randomization studies.","volume":"27","author":"Hemani","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"1","key":"zoi240817r53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2393-14-23","article-title":"The role of gestational diabetes, pre-pregnancy body mass index and gestational weight gain on the risk of newborn macrosomia: results from a prospective multicentre study.","volume":"14","author":"Alberico","year":"2014","journal-title":"BMC Pregnancy Childbirth"},{"issue":"D1","key":"zoi240817r54","doi-asserted-by":"publisher","first-page":"D977","DOI":"10.1093\/nar\/gkac1010","article-title":"The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource.","volume":"51","author":"Sollis","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"zoi240817r55","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/gepi.2018.42.issue-7","article-title":"Bias in mendelian randomization due to assortative mating.","volume":"42","author":"Hartwig","year":"2018","journal-title":"Genet Epidemiol"},{"issue":"5","key":"zoi240817r56","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41588-022-01062-7","article-title":"Within-sibship genome-wide association analyses decrease bias in estimates of direct genetic effects.","volume":"54","author":"Howe","year":"2022","journal-title":"Nat Genet"},{"issue":"1","key":"zoi240817r57","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1038\/s41467-020-17117-4","article-title":"Avoiding dynastic, assortative mating, and population stratification biases in mendelian randomization through within-family analyses.","volume":"11","author":"Brumpton","year":"2020","journal-title":"Nat Commun"},{"issue":"7","key":"zoi240817r58","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrg2813","article-title":"New approaches to population stratification in genome-wide association studies.","volume":"11","author":"Price","year":"2010","journal-title":"Nat Rev Genet"},{"issue":"12","key":"zoi240817r59","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1093\/humrep\/deab224","article-title":"Body mass index and subfertility: multivariable regression and Mendelian randomization analyses in the Norwegian Mother, Father and Child Cohort Study.","volume":"36","author":"Hern\u00e1ez","year":"2021","journal-title":"Hum Reprod"},{"issue":"3","key":"zoi240817r60","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/HYPERTENSIONAHA.121.18415","article-title":"Oral antihypertensives for nonsevere pregnancy hypertension: systematic review, network meta- and trial sequential analyses.","volume":"79","author":"Bone","year":"2022","journal-title":"Hypertension"},{"issue":"10","key":"zoi240817r61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002252.pub4","article-title":"Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.","volume":"10","author":"Abalos","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"zoi240817r62","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018494","article-title":"Impact of chronic hypertension and antihypertensive treatment on adverse perinatal outcomes: systematic review and meta-analysis.","volume":"10","author":"Al Khalaf","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"zoi240817r63","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ajog.2020.03.016","article-title":"Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.","volume":"223","author":"Bellos","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"zoi240817r64","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1161\/HYPERTENSIONAHA.116.07862","article-title":"The CHIPS randomized controlled trial (Control of Hypertension in Pregnancy Study).","volume":"68","author":"Magee","year":"2016","journal-title":"Hypertension"},{"key":"zoi240817r65","doi-asserted-by":"publisher","journal-title":"N Engl J Med","DOI":"10.1056\/NEJMoa2201295"},{"key":"zoi240817r66","journal-title":"Hypertension"},{"issue":"6","key":"zoi240817r67","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jamainternmed.2017.0608","article-title":"\u00df-Blocker exposure in pregnancy and risk of fetal cardiac anomalies.","volume":"177","author":"Duan","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"2","key":"zoi240817r68","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/bdrb.v89:2","article-title":"Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns.","volume":"89","author":"Nakhai-Pour","year":"2010","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"7","key":"zoi240817r69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1010290","article-title":"Estimation of causal effects of a time-varying exposure at multiple time points through multivariable mendelian randomization.","volume":"18","author":"Sanderson","year":"2022","journal-title":"PLoS Genet"},{"issue":"7","key":"zoi240817r70","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/gepi.2016.40.issue-7","article-title":"Bias due to participant overlap in two-sample mendelian randomization.","volume":"40","author":"Burgess","year":"2016","journal-title":"Genet Epidemiol"},{"issue":"3","key":"zoi240817r71","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/ije\/dyw127","article-title":"Commentary: two-sample mendelian randomization: opportunities and challenges.","volume":"45","author":"Lawlor","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"2233","key":"zoi240817r72","doi-asserted-by":"publisher","first-page":"n2233","DOI":"10.1136\/bmj.n2233","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomisation (STROBE-MR): explanation and elaboration.","volume":"375","author":"Skrivankova","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"zoi240817r73","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41569-020-00493-1","article-title":"Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development.","volume":"18","author":"Holmes","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"zoi240817r74","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/ije\/dyy258","article-title":"Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption.","volume":"48","author":"Bowden","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"5","key":"zoi240817r75","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/ije\/dyy092","article-title":"Antibiotics, acetaminophen and infections during prenatal and early life in relation to type 1 diabetes.","volume":"47","author":"Tapia","year":"2018","journal-title":"Int J Epidemiol"},{"issue":"10","key":"zoi240817r77","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrcardio.2017.78","article-title":"Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.","volume":"14","author":"Holmes","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"zoi240817r15","author":"National Institute for Health and Care Excellence"},{"key":"zoi240817r47","author":"R Core Team"},{"key":"zoi240817r2","unstructured":"National Institute for Health and Care Excellence. Hypertension in pregnancy. Clinical Knowledge Summaries. March 20, 2024. Accessed April 27, 2024. https:\/\/cks.nice.org.uk\/topics\/hypertension-in-pregnancy\/background-information\/prevalence\/"},{"key":"zoi240817r32","doi-asserted-by":"crossref","unstructured":"Elsworth? B, Lyon? M, Alexander? T, . The MRC IEU OpenGWAS data infrastructure.? bioRxiv. Preprint posted online August 10, 2020. doi:10.1101\/2020.08.10.244293","DOI":"10.1101\/2020.08.10.244293"},{"key":"zoi240817r37","unstructured":"Norwegian Institute of Public Health. Questionnaires from MoBa. Accessed February 23, 2022. https:\/\/www.fhi.no\/en\/studies\/moba\/for-forskere-artikler\/questionnaires-from-moba\/"},{"key":"zoi240817r40","doi-asserted-by":"crossref","unstructured":"Corfield? EC, Frei? O, Shadrin? AA, . The Norwegian Mother, Father, and Child cohort study (MoBa) genotyping data resource: MoBaPsychGen pipeline v.1.? bioRxiv. Preprint posted online May 7, 2024. doi:10.1101\/2022.06.23.496289?","DOI":"10.1101\/2022.06.23.496289"},{"key":"zoi240817r41","unstructured":"National Health Service Business Services Authority. NHS dictionary of medicines and devices (dm+d) data model R2 v3.2. February 2023. Accessed June 6, 2023. https:\/\/www.nhsbsa.nhs.uk\/pharmacies-gp-practices-and-appliance-contractors\/dictionary-medicines-and-devices-dmd"},{"key":"zoi240817r42","unstructured":"OpenPrescribing: About. Bennett Institute for Applied Data Science. Accessed September 23, 2022. https:\/\/openprescribing.net\/about\/"},{"key":"zoi240817r76","unstructured":"IEU OpenGWAS Project. Systolic blood pressure, automated reading. Accessed May 19, 2023. https:\/\/gwas.mrcieu.ac.uk\/datasets\/ukb-b-20175\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2822872\/barry_2024_oi_240817_1724178893.6127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:00:56Z","timestamp":1724770856000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2822872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.26234","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}